// App-Quantinova.ai

EP1130 : TREATMENT OF IMMUNE THROMBOCYTOPENIA IN THE COVID-19 ERA: FOSTAMATINIB, AN ORAL SPLEEN TYROSINE KINASE INHIBITOR

Researchers

Presenter

  • Nichola Cooper

Principal Investigators

  • Asad Charania

  • Alice Hart

  • Christine Ademokun

  • Robert Numerof

Medical Centers

  • Imperial College, London, United Kingdom

  • Imperial College Healthcare NHS Trust St Marys Hospital, London, United Kingdom

  • Medical Affairs,Rigel Pharmaceuticals, Inc,South San Francisco,United States

  • Epsom and St Helier University Hospitals NHS Trust, Epsom, United Kingdom

  • Imperial College Hospital NHS trust, London, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Autoimmune (AI)

Disease

  • Immune thrombocytopenia

  • Coronavirus disease

Biomarkers

  • N/A

Drug/Treatment

  • Fostamatinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved